Tempo Therapeutics Announces First Patient Dosed in Clinical Trial of TT101 for Tissue Repair in Skin Cancer Surgery

Tempo Therapeutics, Inc. announced the dosing of the first patients in the MOSAIC Trial, a clinical trial for TT101, the company’s lead candidate for tissue regeneration using its proprietary MAP technology. TT101 is a flowable and integrative scaffold, showing non-immunogenic and regenerative tissue responses in large animal studies of soft tissue repair.